Abstract 3599
Background
Palbociclib, the first clinically available oral CDK4/6 inhibitor, in combination with endocrine therapy has become standard of care for HR+/HER2- advanced/metastatic breast cancer (MBC). No real-world studies have examined relative effectiveness of palbociclib plus endocrine therapy compared with endocrine therapy alone. This study compared real-world progression free survival (rwPFS) of palbociclib plus letrozole (PB+LE) vs letrozole alone (LE) for MBC in US routine clinical practices.
Methods
We conducted a retrospective analysis of MBC patients from the Flatiron Health longitudinal database, which contains electronic health records from 275 cancer clinics representing more than 2 million actively treated cancer patients in the US. Between February 2015 and August 2018, 1416 HR+/HER2– MBC women started PB+LE (n = 798) or LE (n = 618) as first-line therapy. Patients were evaluated from start of PB+LE or LE to November 2018, death, or last visit, whichever came first. rwPFS was defined as months from start of PB+LE or LE to death or disease progression based on clinical assessment or evidence by radiographic scan/tissue biopsy. 1:1 propensity score (PS) matching was used to balance patient characteristics.
Results
Of 1416 eligible patients, 906 were 1:1 PS matched (453 for each cohort). Median follow-up was 16.8 months, median age was 68.0 years, 70% were white, and 49.7% had visceral disease. Median rwPFS was 24.5 months (95%CI = 20.7 – 32.7) in PB+LE cohort and 17.1 months (95%CI=13.7—19.8) in LE cohort (HR = 0.68, 95%CI=0.56—0.84, p =.0003). Table presents key patient characteristics and landmark rwPFS rates.Table:
329P Patient characteristics and real-world progressionfree survival (rwPFS)
Variable | PB+LE (N = 453) | LE alone (N = 453) |
---|---|---|
Median age (years) | 68.0 | 68.0 |
White (%) | 69.8 | 70.6 |
Median number of metastatic sites (n) | 2.0 | 2.0 |
Bone only disease (%) | 26.9 | 32.2 |
Visceral disease (%) | 49.7 | 49.7 |
Median rwPFS, months (95%CI) | 24.5 (20.7—32.7) | 17.1 (13.7—19.8) |
rwPFS rate at 6 months (%) | 82.8 | 74.5 |
rwPFS rate at 12 months (%) | 72.1 | 58.9 |
rwPFS rate at 18 months (%) | 60.1 | 48.4 |
rwPFS rate at 24 months (%) | 50.2 | 39.1 |
Median follow-up, months (IQR) | 16.8(8.1—27.1) | 16.8(6.9—26.9) |
PB+LE = Palbociclib plus letrozole; LE = Letrozole alone; IQR = Interquartile Range
Conclusions
The first comparative analysis of a CDK4/6 inhibitor in combination with endocrine therapy compared to endocrine therapy alone provides real-world evidence confirming the findings of PFS benefit demonstrated in clinical trial data for palbociclib in diverse clinical practices.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pfizer Inc.
Funding
Pfizer Inc.
Disclosure
R.M. Layman: Research grant / Funding (institution): Pfizer Inc. X. Liu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. J. Mardekian: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. L. McRoy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc.
Resources from the same session
3902 - The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment – single center experience in setting of no reimbursement in Poland (2011-2015)
Presenter: Agnieszka Badora-Rybicka
Session: Poster Display session 2
Resources:
Abstract
4733 - A Multicentre, International Neoadjuvant (NA), Randomized, Double-blind Phase III Trial comparing FULVESTRANT to a combination of FULVESTRANT and PALBOCICLIB in patients with operable Luminal Breast Cancer (SAFIA Trial)
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 2
Resources:
Abstract
5227 - Outcome of Non-metastatic Male Breast Cancer: 222 patients
Presenter: Ulku Yalcintas Arslan
Session: Poster Display session 2
Resources:
Abstract
5943 - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, Her2 positive breast cancer in a limited resources setting: ML25232 study final results
Presenter: Samir Beslija
Session: Poster Display session 2
Resources:
Abstract
1725 - Final results of scalp cooling for hair preservation: A single- institution prospective study.
Presenter: Dario Loparco
Session: Poster Display session 2
Resources:
Abstract
3713 - Adjuvant Systemic Therapy in Women with Early Breast Cancer and Intermediate Prosigna ROR Scores: Is Chemotherapy Use Declining? Evidence From a Large Practice
Presenter: Lowell Hart
Session: Poster Display session 2
Resources:
Abstract
818 - Management of early breast cancer in women over 90: A 10 year experience
Presenter: Emily Coffey
Session: Poster Display session 2
Resources:
Abstract
1141 - Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early- stage breast cancer.
Presenter: Daniel Reinhorn
Session: Poster Display session 2
Resources:
Abstract
2277 - Hepatitis B screening and incidence of flare among non-metastatic breast cancer patients treated with anthracyclines
Presenter: Zewen Zhang
Session: Poster Display session 2
Resources:
Abstract
2781 - Effect of denosumab on low bone mineral density in postmenopausal Japanese early breast cancer patients receiving aromatase nhibitors : 36-month results
Presenter: Koichi Sakaguchi
Session: Poster Display session 2
Resources:
Abstract